MedTrace Logo

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

NCT07680582 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.

Conditions

Interventions

DRUG

ABO2109 Injection

personalized cancer vaccine

DRUG

Toripalimab

Anti-PD-1 monoclonal antibody

Sponsors & Collaborators

  • Abogen Life Sciences (Shanghai) Co., Ltd.

    collaborator UNKNOWN

  • Suzhou Abogen Biosciences Co., Ltd.

    collaborator INDUSTRY

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Baiyong Shen · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-09
Primary Completion
2028-06-30
Completion
2031-02-09

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680582 on ClinicalTrials.gov